Acute Lymphoblastic Leukemia
Comprehensive care for ALL, including intensive chemotherapy, targeted therapy, and stem cell transplantation.
Acute Lymphoblastic Leukemia
Hematologic Malignancies
Overview
Acute Lymphoblastic Leukemia (ALL) is a rapid, highly aggressive malignancy of the bone marrow and blood, characterized by the uncontrolled proliferation of immature lymphoid progenitor cells, known as lymphoblasts. These abnormal lymphoblasts fail to mature into functional white blood cells (lymphocytes) and rapidly accumulate in the bone marrow, crowding out normal hematopoietic stem cells. This leads to a severe deficiency of normal red blood cells, white blood cells, and platelets.
ALL can arise from B-cell progenitors (B-ALL, about 75-80% of cases) or T-cell progenitors (T-ALL, about 15-20%). While ALL is the most common pediatric cancer (with high cure rates in children), it also occurs in adults, where it represents a therapeutic challenge with a more aggressive course. A major cytogenetic subtype is Philadelphia chromosome-positive ALL (Ph+ ALL), characterized by the t(9;22) translocation, which creates the BCR-ABL1 fusion gene.
Symptoms of ALL develop rapidly, typically over days to weeks, and include severe fatigue, weakness, pale skin (anemia), frequent or persistent infections with fever (neutropenia), easy bruising, nosebleeds, bleeding gums (thrombocytopenia), bone and joint pain, lymphadenopathy (swollen lymph nodes), splenomegaly, hepatomegaly, and symptoms of central nervous system (CNS) involvement such as headaches, vomiting, or cranial nerve palsies, as ALL cells frequently cross the blood-brain barrier.
When to Consult
Upon diagnosis of ALL, abnormal blood counts, fatigue, bruising, bleeding, infections, bone pain, or suspicious blood test results.
What to Bring
CBC, peripheral smear, bone marrow biopsy, cytogenetic studies, FISH testing, molecular testing (BCR-ABL, Ph-like), flow cytometry, and lumbar puncture results.
Risk Factors
Causes
Treatment Options
Intensive Multi-Phase Chemotherapy Protocols
The primary treatment for ALL is intensive, multi-phase combination chemotherapy . The phases include: 1) Induction Therapy (4-6 weeks), using drugs like vincristine, anthracyclines, L-asparaginase, and dexamethasone to destroy the majority of leukemia cells and achieve complete remission; 2) Consolidation/Intensification, utilizing high-dose chemotherapy (e.g., methotrexate, cytarabine) to eliminate residual, dormant cells and prevent relapse; 3) Maintenance Therapy (2-3 years), consisting of lower-dose oral chemotherapy (mercaptopurine and methotrexate) to keep the patient in remission. Central Nervous System (CNS) Prophylaxis, involving intrathecal chemotherapy injected directly into the spinal canal during all phases, is mandatory to prevent CNS relapse.
Targeted Tyrosine Kinase Inhibitors (TKI) for Ph+ ALL
For patients with Philadelphia chromosome-positive ALL (Ph+ ALL), the addition of targeted Tyrosine Kinase Inhibitors (TKIs) to chemotherapy has revolutionized treatment, turning a historically poor-prognosis subtype into a highly treatable one. TKIs specifically block the abnormal BCR-ABL1 tyrosine kinase protein, stopping the growth signals of the leukemia cells. First-generation TKIs like Imatinib, second-generation agents like Dasatinib or Nilotinib, and the third-generation agent Ponatinib (which overcomes the resistant T315I mutation) are administered orally. TKIs are started immediately during induction and continued throughout all phases of treatment.
Monoclonal Antibodies and Bispecific Immunotherapies
Immunotherapy has emerged as a highly effective tool for B-cell ALL, particularly for relapsed, refractory, or MRD-positive disease. Blinatumomab is a Bispecific T-Cell Engager (BiTE) that binds to CD19 on B-lymphoblasts and CD3 on the patient's own T-cells, bringing them together so the T-cells can destroy the leukemia. Inotuzumab Ozogamicin is an antibody-drug conjugate targeting CD22, delivering a powerful chemotherapy toxin directly into the leukemia cells. These targeted immunotherapies achieve high rates of remission with less systemic toxicity than conventional chemotherapy , often serving as a bridge to stem cell transplantation.
Allogeneic Hematopoietic Stem Cell Transplantation
Allogeneic stem cell transplantation (using donor stem cells) is recommended as consolidation therapy for adults and high-risk pediatric patients with ALL in first complete remission, or for patients with relapsed/refractory disease. Following intensive conditioning chemotherapy and/or total body irradiation (TBI) to destroy all residual marrow and leukemia, healthy stem cells from an HLA-matched sibling or unrelated donor are infused. The donor cells reconstruct the patient's immune system and blood cells, providing a powerful 'graft-versus-leukemia' effect, which is the most effective long-term defense against relapse.
Frequently Asked Questions
Q. What is the most effective treatment for Acute Lymphoblastic Leukemia?
The most effective treatment for Acute Lymphoblastic Leukemia depends on the stage, location, molecular profile of the tumor, and the patient's overall health. Dr. R. Srinath Bharadwaj provides personalized protocols including chemotherapy , immunotherapy , targeted therapy , or combination approaches.
Q. Where can I get expert treatment for Acute Lymphoblastic Leukemia in Hyderabad?
You can consult Dr. R. Srinath Bharadwaj, a leading Medical Oncologist, at the American Oncology Institute, Nallagandla, Hyderabad. Call +91 91213 36638 to schedule an appointment.
Q. What documents should I bring for a Acute Lymphoblastic Leukemia consultation?
Please bring all recent biopsy reports, imaging scans (CT, MRI, or PET-CT), tumor markers, blood test results, and any previous treatment or surgery details to help outline your care plan.
Need Treatment?
Schedule a consultation to discuss treatment options for Acute Lymphoblastic Leukemia .